NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Sat Kartar Life to Invest ₹75 Lakh in New 15-Bed Ayurveda Centre in Ludhiana
Sat Kartar Life Limited has approved the establishment of a new 15-bed Ayurveda Hospital and Wellness Centre in Ludhiana, Punjab. The facility will span approximately 4,500 sq. ft. with an estimated investment of ₹75 lakh (~₹0.75 crore), funded through internal accruals and preferential issue proceeds. The center is scheduled to become operational by March 2027, complementing an upcoming 30-bed facility in Amritsar.
உச்சம் நம்பிக்கை
என்ன மாறியதுSat Kartar Life officially initiated plans to open a 15-bed Ayurveda Hospital and Wellness Centre in Ludhiana, Punjab.
ஏன் இது முக்கியம்The project advances the company's stated strategy to vertically expand into higher-margin (targeted 25-30% EBITDA) Ayurvedic healthcare services to complement its D2C product sales.
Estimated Investment: ₹75 லட்சம்Proposed Capacity: 15 BedsFacility Area: 4500 sq. ft.Target Operational Date: மார்ச் 2027Capex vs Net Worth: ~0.99%
📅 குறுகிய காலம்Limited direct impact given the small capex quantum of ₹75 lakh and an execution window extending to March 2027.
📈 நீண்ட காலம்Serves as an incremental step in building a hospital network aimed at capturing high-margin Ayurvedic therapies and diversifying beyond core D2C products.
⚠ அபாய எச்சரிக்கைகள்
Execution and regulatory approval delays beyond March 2027
Ramp-up and utilization risk in physical healthcare centres
👀 கவனிக்க வேண்டியவை
Track statutory approvals and project commissioning by March 2027, along with progress on the upcoming 30-bed facility in Amritsar.
Sat Kartar Life to Invest ₹1.25 Cr to Set Up 30-Bed Ayurveda Hospital in Jaipur
Sat Kartar Life Limited has announced plans to establish a new 30-bed Ayurveda Hospital and Wellness Centre spanning 16,000 sq. ft. in Jaipur, Rajasthan. The estimated investment is approximately ₹1.25 crore, which is relatively modest compared to its net worth of ₹76 crore (around 1.6%). The project will be funded via internal accruals and preferential issue proceeds, with commercial operations targeted by March 2027 subject to regulatory approvals. This marks the company's planned vertical integration into higher-margin hospital wellness services to complement its D2C product portfolio.
உச்சம் நம்பிக்கை
என்ன மாறியதுSat Kartar Life approved and announced a proposal to set up a new 30-bed Ayurveda hospital in Jaipur with ₹1.25 crore investment.
ஏன் இது முக்கியம்Enables the company to execute its strategic roadmap of vertical expansion into Ayurvedic healthcare services, targeting higher-margin service revenue alongside its existing D2C products.
Estimated Investment: ₹1.25 CroresInvestment vs Net Worth: ~1.6%Proposed Bed Capacity: 30 BedsEstimated Area: 16,000 sq. ft.Target Operational Date: மார்ச் 2027
📅 குறுகிய காலம்Limited direct financial impact in the short term as the facility requires approvals and build-out through March 2027.
📈 நீண்ட காலம்Supports diversification from product-only D2C sales into full-service healthcare, which could enhance customer lifetime value and improve operating margins if successfully scaled.
⚠ அபாய எச்சரிக்கைகள்
Execution and regulatory delay risks (operational readiness targeted by March 2027)
Hospital capacity ramp-up and local patient acquisition risks
👀 கவனிக்க வேண்டியவை
Track licensing and regulatory clearances over the coming quarters, alongside progress on site readiness ahead of the March 2027 operational deadline.
Sat Kartar Life Receives NSE Approval for 5,50,000 Convertible Warrants via Preferential Issue
Sat Kartar Life Limited has received in-principle approval from the National Stock Exchange of India (NSE) under Regulation 28(1) of SEBI LODR Regulations for a proposed preferential issue. The approval covers the issuance of 5,50,000 fully convertible warrants, following the company's application submitted on October 01, 2026. The approval letter (Ref: NSE/LIST/57819) was granted on November 03, 2026. The issue price, total capital to be raised, and allottee details were not disclosed in this specific filing.
உச்சம் நம்பிக்கை
என்ன மாறியதுSat Kartar Life cleared a key regulatory milestone by securing NSE's in-principle approval to issue 5,50,000 convertible warrants.
ஏன் இது முக்கியம்Enables the company to proceed with preferential capital raising, which will inject equity funds to support its ongoing capacity expansion and growth plans, albeit with future equity dilution.
Warrants to be issued: 5,50,000Application date: அக்டோபர் 01, 2026Approval date: நவம்பர் 03, 2026Total fundraise value: வெளியிடப்படவில்லை
📅 குறுகிய காலம்Clearance allows the company to proceed with the allotment of warrants subject to shareholder and statutory processes.
📈 நீண்ட காலம்Conversion of warrants will expand the equity base and supply growth capital, though long-term value depends on deployment efficiency and pricing.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution upon warrant conversion
Pricing and capital quantum not disclosed in this announcement
👀 கவனிக்க வேண்டியவை
Track subsequent filings for the allotment of warrants, issue price, total fundraise quantum, and dilution impact on the existing equity base.
SATKARTAR Signs LoI for 25-Bed Therapy Centre in Lucknow with ₹1 Cr Outlay
Sat Kartar Life Limited has signed a Letter of Intent to establish a new 25-bed Hospital-cum-Therapy Centre in Lucknow, Uttar Pradesh. The project spans approximately 9,000 sq. ft. with an estimated investment of ₹1 Crore, funded via internal accruals and preferential issue proceeds. The facility is targeted to become operational by February 2027, subject to necessary approvals. The capex of ₹1 Crore represents ~1.3% of the company's net worth (₹76 Cr), indicating a modest financial outlay aligned with its vertical healthcare push.
உச்சம் நம்பிக்கை
என்ன மாறியதுSigned a Letter of Intent to set up a new 25-bed hospital-cum-therapy center in Lucknow.
ஏன் இது முக்கியம்Advances the company's strategic pivot into Ayurvedic healthcare services (targeting 25-30% EBITDA margins) alongside its existing D2C products.
Bed capacity: 25 BedsEstimated Investment: ₹1 Crore (Approx.)Estimated Area: Approximately 9000 sq. ft.Expected Operational Date: பிப்ரவரி, 2027Capex to Net Worth: ~1.3%
📅 குறுகிய காலம்Low immediate financial impact as operational commencement is slated for February 2027 with a modest outlay of ₹1 Crore.
📈 நீண்ட காலம்Validates management's strategy to expand high-margin hospital and therapy services, complementing its core Ayurvedic product line.
⚠ அபாய எச்சரிக்கைகள்
Subject to regulatory licenses and operational readiness
Execution timeline spans over three months until February 2027
👀 கவனிக்க வேண்டியவை
Track progress toward licensing approvals and the targeted operational commencement date of February 2027.
Sat Kartar Life H1 FY27: Revenue Up 26.4% to ₹113.9 Cr, Guides ₹500 Cr for FY28
Sat Kartar Life Limited reported its H1 FY27 earnings conference call transcript, posting consolidated revenue of ₹113.9 crores (up 26.4% YoY) and net profit of ₹9.25 crores (up 26.7% YoY). EBITDA climbed 47.7% to ₹14.5 crores as operating margins expanded by 180 bps to 12.7%. The company is accelerating its transition into an integrated healthcare provider, achieving operational breakeven at its first 30-bed Delhi hospital and planning five new hospital launches in the current quarter. Management reaffirmed a long-term target of ₹500 crores in revenue for FY28, with ₹150–200 crores projected from the hospital vertical.
உச்சம் நம்பிக்கை
என்ன மாறியதுSubmission of the transcript for the H1 FY27 earnings conference call held on October 26, 2026.
ஏன் இது முக்கியம்Demonstrates management's shift from a pure D2C product company to a higher-margin integrated Ayurveda hospital model, aiming to sustain 30-35% revenue growth.
📅 குறுகிய காலம்Positive sentiment from strong operating margin expansion and breakeven of the first hospital, with US sales launch scheduled for November.
📈 நீண்ட காலம்The company's target of reaching ₹500 crore revenue by FY28 relies heavily on adding 300 hospital beds and churning existing D2C patient data to improve blended margins.
⚠ அபாய எச்சரிக்கைகள்
High marketing spend maintained at ~40% in the product vertical
Execution risks in scaling capital-intensive hospital facilities across multiple locations
Low current AI conversion (<1%) despite previous expectations
👀 கவனிக்க வேண்டியவை
Track the rollout and occupancy of the 5 new planned hospitals in H2 FY27 and monitor the commercial launch of the US operations starting November.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Sat Kartar Life H1 FY27 Net Profit Rises 22% YoY to ₹9.49 Cr, Revenue at ₹106.47 Cr
Sat Kartar Life Limited reported its unaudited standalone financial results for the half year ended September 30, 2026. Standalone revenue from operations grew 20.5% YoY to ₹106.47 crore compared to ₹88.35 crore in H1 FY26. Standalone net profit reached ₹9.49 crore, up 21.9% YoY from ₹7.79 crore in H1 FY26. Additionally, the company disclosed zero deviation in the utilization of its ₹33.80 crore IPO proceeds (₹25.82 crore utilized) and ₹47.22 crore preferential issue proceeds (₹4.20 crore utilized).
உச்சம் நம்பிக்கை
என்ன மாறியதுSat Kartar Life reported its half-yearly financial results for H1 FY27 alongside clean limited review reports and funds utilization disclosures.
ஏன் இது முக்கியம்Demonstrates consistent top-line and bottom-line expansion (~20-22% YoY) aligning closely with its 25-30% long-term growth guidance while maintaining strong capital discipline.
📅 குறுகிய காலம்Stable operational execution and clean auditor review without deviation in fund utilization should support steady sentiment.
📈 நீண்ட காலம்Growth remains tied to successful scaling of healthcare/Ayurvedic hospitals and deployment of the ₹47.22 crore preferential issue proceeds.
⚠ அபாய எச்சரிக்கைகள்
Subsidiary financials for interim periods were based solely on unreviewed management statements
High marketing and advertising spend (₹72.31 crore in standalone other expenses for H1 FY27)
👀 கவனிக்க வேண்டியவை
Track the deployment pace of the ₹43.02 crore unutilized preferential issue funds earmarked for healthcare expansion, and monitor operating margin trends amid high marketing expenses.
Sat Kartar Reports H1 FY27 Revenue of ₹113.9 Cr, Targets 300 Hospital Beds by FY27
Sat Kartar Life Limited published its H1 FY27 investor presentation highlighting revenues of ₹113.9 crore, EBITDA of ₹14.5 crore (12.7% margin), and PAT of ₹9.2 crore. The company is actively transitioning from pure D2C Ayurvedic product retail into an integrated healthcare platform, having operationalized its first 30-bed hospital in Delhi which reached breakeven in September 2026. The company is targeting aggressive hospital expansion to ~300 beds by FY27 and ~1,000 beds by FY28 at an estimated unit capex of ₹5–6 lakh per bed. Operating cash flow for H1 FY27 was negative at -₹6.9 crore, impacted by a ₹19.0 crore working capital absorption.
உச்சம் நம்பிக்கை
என்ன மாறியதுSat Kartar disclosed comprehensive H1 FY27 financial results along with strategic rollout guidance of scaling Ayurvedic hospital capacity from 30 beds to ~1,000 beds by FY28.
ஏன் இது முக்கியம்The pivot from pure D2C product sales to clinical healthcare services adds a higher-margin recurring revenue stream, but requires disciplined execution and capex management.
H1 FY27 Revenue: ₹113.9 கோடிH1 FY27 PAT: ₹9.2 கோடிEBITDA Margin (H1 FY27): 12.7%Target Beds by FY27: 300Average Cost per Bed: ₹5–6 lakhNet Cash from Operations (H1 FY27): -₹6.9 கோடி
📅 குறுகிய காலம்Market sentiment may react positively to the 12.7% operating margins and ambitious hospital expansion roadmap, tempered by negative operating cash flow.
📈 நீண்ட காலம்If successfully executed, expanding to 1,000 beds by FY28 could structurally improve customer lifetime value, margins, and brand equity beyond pure D2C wellness products.
⚠ அபாய எச்சரிக்கைகள்
Negative operating cash flows (-₹6.9 Cr in H1 FY27) driven by rising working capital needs
Execution risks in scaling from 30 to 300 beds by FY27 across new geographies
High marketing and customer acquisition dependency typical of D2C wellness businesses
👀 கவனிக்க வேண்டியவை
Track the pace of hospital rollouts towards the 300-bed FY27 target and monitor working capital levels to see if operating cash flows turn positive.
Sat Kartar Life to Invest ₹1.5 Cr in 30-Bed Ayurvedic Hospital in Amritsar
Sat Kartar Life Limited has approved the establishment of a new 30-bed hospital-cum-therapy centre in Amritsar, Punjab. The facility will span approximately 13,000 sq. ft. of covered area with an estimated investment of ₹1.5 crore, funded entirely through IPO proceeds. The project is expected to be operational by March 31, 2027, subject to regulatory clearances and operational readiness. This marks the company's planned expansion into higher-margin Ayurvedic hospital services.
உச்சம் நம்பிக்கை
என்ன மாறியதுSat Kartar Life has initiated a greenfield hospital-cum-therapy centre project in Amritsar, Punjab.
ஏன் இது முக்கியம்The company is executing its stated strategy to enter Ayurvedic hospital operations, a segment management projects to deliver 25-30% EBITDA margins.
📅 குறுகிய காலம்Limited immediate operational impact as commercial rollout is slated for March 2027, but signals ongoing utilization of IPO proceeds.
📈 நீண்ட காலம்Supports vertical integration into therapy centers which can offer higher customer retention and EBITDA margins (targeted at 25-30%) compared to pure retail D2C.
⚠ அபாய எச்சரிக்கைகள்
Execution timeline extending to March 2027 (approx. 5 months)
Regulatory and licensing approvals pending
👀 கவனிக்க வேண்டியவை
Track the receipt of necessary healthcare licenses and statutory approvals over the next few quarters, alongside project execution milestones leading up to March 2027.
Sat Kartar Life Plans ₹9.46 Cr Preferential Warrant Issue to Promoters; Calls EGM on Oct 23
Sat Kartar Life Limited has issued a notice convening an Extraordinary General Meeting (EGM) on October 23, 2026, to seek shareholder approval for issuing up to 5,50,000 fully convertible warrants on a preferential basis to the promoter/promoter group. The warrants are priced at ₹172 each, totaling up to ₹9.46 crore. A minimum of 25% (₹2.365 crore) is payable on subscription, with the remaining 75% (₹7.095 crore) due upon warrant conversion within 18 months. The cut-off date for e-voting is October 16, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formally notified shareholders of an EGM to approve a ₹9.46 crore preferential warrant allotment to promoters.
ஏன் இது முக்கியம்The infusion of ₹9.46 crore provides growth capital to support ongoing expansions while signaling promoter financial commitment.
Warrants issue size: ₹9,46,00,000Number of warrants: 5,50,000Issue price per warrant: ₹172Upfront subscription (25%): ₹2,36,50,000EGM Date: அக்டோபர் 23, 2026
📅 குறுகிய காலம்Market sentiment may be supported by promoter capital backing, with focus shifting to the shareholder vote on October 23, 2026.
📈 நீண்ட காலம்If converted over the 18-month window, the ₹9.46 crore equity capital will strengthen the balance sheet and modestly expand the equity base.
⚠ அபாய எச்சரிக்கைகள்
Equity dilution upon full conversion of 5,50,000 warrants
Promoter warrants carry an 18-month exercise window; conversion is contingent on full payment of the remaining 75%
👀 கவனிக்க வேண்டியவை
Track the voting outcome of the EGM on October 23, 2026, and monitor subsequent warrant subscription and allotment within the regulatory 15-day timeline.
Sat Kartar Life Board Approves ₹9.46 Cr Convertible Warrants to Promoters at ₹172/Share
Sat Kartar Life Limited's Board has approved the issuance of up to 5,50,000 convertible warrants on a preferential basis to promoter group entities, raising up to ₹9.46 crore. The issue price is fixed at ₹172 per warrant, which is an 18.20% premium over the SEBI ICDR floor price of ₹145.51. Upon full conversion within 18 months, promoter shareholding will increase from 54.20% to 55.52%. The company has scheduled an Extraordinary General Meeting (EGM) on October 23, 2026, to seek shareholder approval, with a voting cut-off date of October 16, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe Board approved a ₹9.46 crore preferential warrant issue entirely to promoters at an 18.20% premium over the floor price.
ஏன் இது முக்கியம்Promoters are injecting fresh equity at a premium, signaling confidence and strengthening capital for business expansion in Ayurveda and hospital services without external leverage.
Total Fundraise Amount: ₹9,46,00,000Number of Warrants: 5,50,000Issue Price per Warrant: ₹172Floor Price: ₹145.51Premium over Floor Price: 18.20%Post-Issue Promoter Holding: 55.52%
📅 குறுகிய காலம்Positive sentiment likely due to promoters infusing capital at an 18.2% premium over the statutory floor price. Focus shifts to the EGM on October 23, 2026.
📈 நீண்ட காலம்Provides incremental growth capital to scale its integrated healthcare and hospital services platform while modestly increasing promoter alignment.
⚠ அபாய எச்சரிக்கைகள்
Dilution of public shareholding from 45.80% to 44.48%
Warrant holders have up to 18 months to convert; remaining 75% capital inflow is contingent on conversion
👀 கவனிக்க வேண்டியவை
Track voting results from the October 23, 2026 EGM and subsequent receipt of the 25% upfront subscription capital. Monitor deployment of funds into the Ayurveda products and hospital platform expansions.
Sat Kartar Signs LOI to Add 20-Bed Ayurvedic Hospital in Dehradun for ₹70 Lakh
Sat Kartar Life Limited has signed a Letter of Intent (LOI) to establish a new 20-bed hospital-cum-therapy centre on Rajpur Road, Dehradun, Uttarakhand. The facility will span approximately 7,000 sq. ft. with an estimated investment of ₹70 Lakh funded via IPO funds. It is targeted to be operational by December 15, 2026, subject to regulatory approvals. This move aligns with the company's stated strategy to vertically integrate into high-margin (25-30% EBITDA) Ayurvedic hospital services.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company entered into an LOI to set up a new 20-bed hospital and therapy centre in Dehradun.
ஏன் இது முக்கியம்The ₹70 Lakh capex allows the company to vertically expand into Ayurvedic hospital operations, a segment management projects to generate 25-30% EBITDA margins.
📅 குறுகிய காலம்Neutral to mildly positive as the announcement is currently at the Letter of Intent stage with a modest initial capex outlay.
📈 நீண்ட காலம்If successfully scaled and replicated, the transition into hospital-cum-therapy centres supports diversification from pure D2C wellness products into higher-margin integrated wellness services.
⚠ அபாய எச்சரிக்கைகள்
Preliminary LOI stage; subject to definitive agreements and statutory healthcare licences
Execution and operational delays ahead of the December 2026 launch target
👀 கவனிக்க வேண்டியவை
Track the signing of definitive agreements and the receipt of regulatory licences ahead of the targeted December 15, 2026 commissioning date.
₹1 Cr Investment for New 10-15 Bed Ayurvedic Hospital in Gurugram
Sat Kartar Life Limited is establishing a new 4,000 sq. ft. hospital-cum-therapy centre in Gurugram, Haryana, with an estimated investment of ₹1 crore. The facility will feature 10-15 beds and is slated to become operational by October 15, 2026, funded through IPO proceeds. This expansion aligns with the company's strategy to enter the high-margin Ayurvedic hospital segment, which targets 25-30% EBITDA margins. While the capex is small (~0.9%) relative to the March 2026 quarterly revenue of ₹110.62 crore, it represents a key vertical integration step.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is expanding its business model from purely D2C Ayurvedic products to include physical healthcare infrastructure and therapy services.
ஏன் இது முக்கியம்This vertical expansion into hospital services is expected to be EBITDA accretive and provides a higher-margin revenue stream compared to traditional product sales.
Estimated Investment: ₹1 கோடிProposed Bed Capacity: 10-15 bedsEstimated Area: 4,000 sq. ft.Operational Date: 15th அக்டோபர், 2026Investment vs Mar 2026 Revenue: ~0.9%
📅 குறுகிய காலம்The announcement is likely to be viewed positively as it demonstrates the deployment of IPO funds into high-margin expansion projects.
📈 நீண்ட காலம்If successful, the transition to a service-integrated model could improve customer retention and structural margins over the next 2-3 years.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approvals for hospital operations
Execution risk in managing physical healthcare facilities
Small scale of initial investment relative to total revenue
👀 கவனிக்க வேண்டியவை
Monitor the timely commencement of operations by October 2026 and subsequent updates on capacity utilization, which the company targets at 80-90% within the first year.
₹0.70 Dividend and ₹164.5 Cr Related Party Transactions Proposed in 14th AGM Notice
Sat Kartar Life Limited has scheduled its 14th AGM for August 28, 2026, to approve a final dividend of ₹0.70 per share for FY 2025-26. The company is seeking shareholder approval for significant Related Party Transactions (RPT) totaling ₹164.5 crore for FY 2026-27, primarily for trade and marketing with subsidiaries. For the full year FY 2025-26, the company reported a net profit of ₹17.10 crore, a significant increase from ₹9.81 crore in the previous year. The record date for dividend eligibility is set for August 21, 2026.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its AGM schedule, dividend payout details, and sought authorization for substantial inter-company transactions for the next year.
ஏன் இது முக்கியம்The proposed RPT limit of ₹164.5 crore is significant compared to the company's quarterly revenue of ₹110.62 crore, indicating a business model heavily reliant on subsidiary-led distribution and marketing.
Dividend per share: ₹0.70Total RPT Limit (FY27): ₹164.5 கோடிFY26 Net Profit: ₹17.10 கோடிRPT vs Annualized Revenue: ~37%ரெக்கார்ட் தேதி: ஆகஸ்ட் 21, 2026
📅 குறுகிய காலம்The stock may see neutral to slightly positive interest leading up to the dividend record date of August 21.
📈 நீண்ட காலம்The company's long-term trajectory depends on the successful integration of its subsidiaries and the efficiency of its high-spend D2C marketing model.
⚠ அபாய எச்சரிக்கைகள்
High volume of Related Party Transactions (₹164.5 cr)
Heavy reliance on subsidiary-led trade
High customer acquisition costs in the D2C segment
👀 கவனிக்க வேண்டியவை
Investors should monitor the approval of the high-value Related Party Transactions at the AGM and track the execution of the US expansion through the newly formed subsidiary Sat Kartar USA INC.
₹0.70 Final Dividend Recommended; Record Date Set for August 21, 2026
Sat Kartar Life Limited has recommended a final dividend of ₹0.70 per equity share (7% of face value) for the financial year ended March 31, 2026. The Board has fixed August 21, 2026, as the record date for determining shareholder eligibility for the dividend and AGM e-voting. The 14th Annual General Meeting is scheduled for August 28, 2026. This follows a March 2026 quarter where the company reported a net profit of ₹9.80 crore on revenue of ₹110.62 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from its financial reporting phase to the dividend distribution and annual governance phase for FY26.
ஏன் இது முக்கியம்The dividend payout confirms the company's intent to return capital to shareholders following a profitable quarter. The re-appointment of auditors for five years provides stability in financial oversight.
Final Dividend: ₹0.70 per shareDividend as % of Face Value: 7%ரெக்கார்ட் தேதி: 21-ஆக.-2026AGM Date: 28-ஆக.-2026Mar 2026 Net Profit: ₹9.80 கோடி
📅 குறுகிய காலம்The stock may experience neutral to slightly positive sentiment as it approaches the record date for the dividend payout.
📈 நீண்ட காலம்The dividend is routine; long-term value will be driven by the company's ability to scale manufacturing utilization from 10% to 50% and execute its US D2C expansion.
⚠ அபாய எச்சரிக்கைகள்
High customer acquisition costs (2.6% conversion for paid search)
Supply chain risks linked to geopolitical instability
👀 கவனிக்க வேண்டியவை
Investors seeking the dividend should ensure they hold the shares before the ex-dividend date (typically one business day prior to the August 21 record date). Monitor the AGM for updates on the proposed US market expansion and Ayurvedic hospital margins.
₹0.70 Dividend Recommended; 14th AGM Scheduled for August 28, 2026
Sat Kartar Life Limited has recommended a final dividend of ₹0.70 per equity share (7% of ₹10 face value) for the financial year ended March 31, 2026. The 14th Annual General Meeting (AGM) is scheduled for August 28, 2026, with the record date for dividend eligibility set as August 21, 2026. The board also approved the re-appointment of M/S. Nidhi Bansal & Co. as statutory auditors for a five-year term. This follows a March 2026 quarter where the company reported a net profit of ₹9.80 crore on revenue of ₹110.62 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized its FY26 dividend payout and scheduled its annual shareholder meeting and auditor re-appointment.
ஏன் இது முக்கியம்The dividend provides a tangible yield to shareholders, while the 5-year auditor term ensures continuity in financial governance during the company's planned expansion phase.
Dividend per share: ₹0.70ரெக்கார்ட் தேதி: ஆகஸ்ட் 21, 2026AGM Date: ஆகஸ்ட் 28, 2026Mar 2026 Revenue: ₹110.62 கோடிMar 2026 Net Profit: ₹9.80 கோடிAuditor Term: 5 years
📅 குறுகிய காலம்The stock may see mild positive interest leading up to the August 21 record date as investors position for the dividend payout.
📈 நீண்ட காலம்Limited structural impact from this routine filing; long-term value depends on the execution of the AI-driven sales model and Ayurvedic hospital expansion.
👀 கவனிக்க வேண்டியவை
Investors should note the record date of August 21, 2026, for dividend eligibility and watch for management commentary during the August 28 AGM regarding US market expansion plans.
Sat Kartar Life Recommends ₹0.70 Dividend and Re-appoints Auditor for 5 Years
Sat Kartar Life Limited has recommended a final dividend of ₹0.70 per equity share (7% of face value) for FY26, following a March 2026 quarter where it reported a net profit of ₹9.80 crore. The board also approved the re-appointment of M/S. Nidhi Bansal & Co. as statutory auditors for a five-year term, ensuring continuity in financial oversight. The record date for the dividend and the 14th Annual General Meeting (AGM) e-voting has been set for August 21, 2026. The AGM is scheduled for August 28, 2026, to seek shareholder approval for these proposals.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has transitioned from its board-level proposal to formalizing the dividend payout and auditor tenure extension for shareholder approval.
ஏன் இது முக்கியம்The dividend provides a tangible cash return to shareholders, representing approximately 11.25% of the reported March quarter EPS of ₹6.22, while the auditor re-appointment maintains governance stability.
Final Dividend: ₹0.70 per shareDividend as % of EPS (Mar Q): 11.25%ரெக்கார்ட் தேதி: ஆகஸ்ட் 21, 2026Auditor Term: 5 yearsMarch 2026 Revenue: ₹110.62 கோடி
📅 குறுகிய காலம்The stock may experience neutral to slightly positive sentiment leading up to the August 21 record date as investors position for the dividend.
📈 நீண்ட காலம்Limited structural impact; the dividend and auditor appointment are routine corporate actions reflecting stable operations.
👀 கவனிக்க வேண்டியவை
Investors should note the record date of August 21, 2026, to be eligible for the dividend and monitor the AGM outcomes on August 28 for formal shareholder approval.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
